MX342967B - Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. - Google Patents

Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.

Info

Publication number
MX342967B
MX342967B MX2012007082A MX2012007082A MX342967B MX 342967 B MX342967 B MX 342967B MX 2012007082 A MX2012007082 A MX 2012007082A MX 2012007082 A MX2012007082 A MX 2012007082A MX 342967 B MX342967 B MX 342967B
Authority
MX
Mexico
Prior art keywords
renal
interleukin
immunoglobulin
growth factor
prognosis
Prior art date
Application number
MX2012007082A
Other languages
English (en)
Spanish (es)
Other versions
MX2012007082A (es
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2012007082A publication Critical patent/MX2012007082A/es
Publication of MX342967B publication Critical patent/MX342967B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012007082A 2009-12-20 2010-12-20 Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. MX342967B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28832709P 2009-12-20 2009-12-20
US30886110P 2010-02-26 2010-02-26
US41087910P 2010-11-06 2010-11-06
US41088010P 2010-11-06 2010-11-06
US41087810P 2010-11-06 2010-11-06
US41087510P 2010-11-06 2010-11-06
PCT/US2010/061377 WO2011075744A1 (en) 2009-12-20 2010-12-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2012007082A MX2012007082A (es) 2012-11-06
MX342967B true MX342967B (es) 2016-10-19

Family

ID=44167738

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007082A MX342967B (es) 2009-12-20 2010-12-20 Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.

Country Status (13)

Country Link
US (3) US10830773B2 (https=)
EP (2) EP3112871B1 (https=)
JP (2) JP5763098B2 (https=)
KR (2) KR102003258B1 (https=)
CN (2) CN104698161A (https=)
AU (2) AU2010330735B2 (https=)
CA (1) CA2784889C (https=)
EA (1) EA201290387A1 (https=)
ES (2) ES2818138T3 (https=)
HK (1) HK1211082A1 (https=)
MX (1) MX342967B (https=)
NZ (3) NZ600828A (https=)
WO (1) WO2011075744A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501456A (ja) 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
ES2836218T3 (es) 2008-10-21 2021-06-24 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en) 2009-02-06 2015-08-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2774223A1 (en) * 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010315008B2 (en) 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) 2010-02-26 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) 2010-06-23 2015-05-22 Astute Medical Inc
NZ606124A (en) * 2010-06-23 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013541005A (ja) * 2010-09-24 2013-11-07 アスチュート メディカル，インコーポレイテッド ヒアルロン酸を使用した腎損傷の評価のための方法ならびに組成物
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
US20140171522A1 (en) * 2011-07-09 2014-06-19 Astute Medical, Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT2748605T (pt) * 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
EP3282257A1 (en) * 2011-11-22 2018-02-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP3699591A1 (en) * 2012-04-02 2020-08-26 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
EP2841945A4 (en) * 2012-04-24 2016-04-27 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING OF STROKE OR OTHER BRAINS
AU2013296231A1 (en) * 2012-08-03 2015-03-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2882767B1 (en) * 2012-08-11 2023-07-12 Astute Medical, Inc. Evaluating renal injury using hyaluronic acid
EP3428649B1 (en) * 2012-09-12 2022-03-23 Roche Diagnostics GmbH Identification of patients with abnormal fractional shortening
EP2923204A1 (en) * 2012-10-31 2015-09-30 Astute Medical, Inc. Quantitative lateral flow assay
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2962109A4 (en) * 2013-02-26 2016-12-07 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP2962104B1 (en) 2013-02-26 2018-04-04 Astute Medical, Inc. Lateral flow assay device with test strip retainer
CA3184836A1 (en) * 2013-05-14 2014-11-20 Metabolon, Inc. Biomarkers related to kidney function and methods using the same
US20160146832A1 (en) * 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20160039682A (ko) 2013-08-07 2016-04-11 아스튜트 메디컬 인코포레이티드 생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정
JP2017501211A (ja) 2013-11-06 2017-01-12 アスチュート メディカル，インコーポレイテッド 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
CN110007084B (zh) * 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CA2965153C (en) * 2014-10-20 2023-10-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016083374A1 (en) 2014-11-25 2016-06-02 F. Hoffmann-La Roche Ag Biomarkers of fast progression of chronic kidney disease
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017246588A1 (en) * 2016-04-08 2018-09-27 Centre National De La Recherche Scientifique - Cnrs - Methods and kits for diagnosing postoperative pulmonary infections in patients who underwent surgery
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
WO2018035340A1 (en) 2016-08-17 2018-02-22 The Regents Of The University Of California A novel immunoprobe-based method to assess organ injury status through a biofluid-based cell-free dna (cfdna) assay
CN110352073A (zh) 2016-10-28 2019-10-18 机敏医药股份有限公司 针对timp-2的抗体用于改善肾功能的用途
EP4063853A1 (en) * 2017-01-12 2022-09-28 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
CN110753700A (zh) * 2017-05-07 2020-02-04 机敏医药股份有限公司 胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途
US11771113B2 (en) 2017-05-31 2023-10-03 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
WO2019138430A1 (en) * 2018-01-15 2019-07-18 Shukla Rashmi A time-based semi-quantitative and quantitative lateral flow assay (lfa) for early detection of renal injury
WO2019144081A1 (en) 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits
EP3821254A1 (en) 2018-07-14 2021-05-19 Mars Incorporated Biomarkers and test models for chronic kidney disease
CN111289756A (zh) * 2018-12-10 2020-06-16 北京师范大学 卵巢癌肺转移成瘤相关的尿液标志物
RU2726314C1 (ru) * 2019-11-15 2020-07-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования
CN113252895A (zh) * 2020-02-10 2021-08-13 首都医科大学附属北京世纪坛医院 血清组织蛋白酶d在淋巴水肿疾病中的应用
JP7758266B2 (ja) 2020-06-01 2025-10-22 マース インコーポレーテッド イヌの慢性腎臓病のためのシステム及び方法
CN111999363B (zh) * 2020-08-17 2022-09-02 遵义医科大学附属医院 一种用于kim-1蛋白的无酶电化学免疫检测系统及其制备和使用方法
EP4263383A4 (en) 2020-12-17 2024-10-23 Nephrosant, Inc. KITS FOR STABILIZATION OF URINE SAMPLES
EP4330681A2 (en) * 2021-04-30 2024-03-06 Roche Diagnostics GmbH Igfbp7 marker panels for early detection of sepsis
CN113552369B (zh) * 2021-07-23 2023-10-20 江苏省中医院 蛋白标志物联合用于2型糖尿病、2型糖尿病肾病的诊断的用途

Family Cites Families (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998057U (ja) 1982-12-23 1984-07-03 東陶機器株式会社 ユニツトバスル−ム
SU1429031A1 (ru) 1986-06-20 1988-10-07 Калининский Государственный Медицинский Институт Способ дифференциальной диагностики гломерулонефрита и пиелонефрита
CA1330302C (en) 1988-01-18 1994-06-21 Miroslav Rybak Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1997044460A1 (en) 1996-05-24 1997-11-27 Biogen, Inc. Modulators of tissue regeneration
US5753455A (en) 1996-09-03 1998-05-19 Bayer Corporation Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
EP1151101A4 (en) * 1998-12-18 2002-10-09 Human Genome Sciences Inc PROSTACYCLIN-STIMULATING FACTOR-2
ATE376187T1 (de) 1998-12-21 2007-11-15 Univ Monash Nachweis von erkrankungen der nieren und behandlung
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
ATE368858T1 (de) 2000-03-10 2007-08-15 Univ Geneve Verfahren zur diagnose von transmissiblen spongiformen encephalopathien
RU2180965C1 (ru) 2000-07-03 2002-03-27 Габбасова Наталья Вадимовна Способ дифференциальной диагностики заболеваний почек
WO2002054081A2 (en) 2000-12-29 2002-07-11 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
CA2442820A1 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20040126767A1 (en) * 2002-12-27 2004-07-01 Biosite Incorporated Method and system for disease detection using marker combinations
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030003588A1 (en) 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
BR0211468A (pt) 2001-07-24 2004-11-23 Univ Yale Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero
JP2003081838A (ja) 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd グルコサミン製剤
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US8404229B2 (en) 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
GB0130557D0 (en) * 2001-12-20 2002-02-06 Serono Internat S A Proteins
WO2003075016A1 (en) 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
WO2003081201A2 (en) 2002-03-21 2003-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
US7138229B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US7138230B2 (en) * 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
WO2004005934A2 (en) 2002-07-04 2004-01-15 Oxford Glycosciences (Uk) Ltd Toxicity markers
US6941172B2 (en) 2002-11-18 2005-09-06 Zvi Nachum Method and device for restoring kidney function using electromagnetic stimulation
US20060063156A1 (en) 2002-12-06 2006-03-23 Willman Cheryl L Outcome prediction and risk classification in childhood leukemia
WO2004059293A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1791797A (zh) 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
US7560244B2 (en) 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
US20050084880A1 (en) 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions
NZ588323A (en) 2003-07-17 2012-04-27 Pacific Edge Biotechnology Ltd Markers for the detection of gastric cancer
US20050148029A1 (en) 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
GB0329288D0 (en) 2003-12-18 2004-01-21 Inverness Medical Switzerland Monitoring method and apparatus
CA2560200A1 (en) 2004-03-17 2005-09-22 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Cd44-targeting for reducing/preventing ischemia-reperfusion-injury
AU2005236075A1 (en) 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
FR2872579B1 (fr) 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US7588892B2 (en) 2004-07-19 2009-09-15 Entelos, Inc. Reagent sets and gene signatures for renal tubule injury
US20080038192A1 (en) 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
WO2006010529A1 (en) 2004-07-28 2006-02-02 F. Hoffmann-La Roche Ag Timp-2 as target/marker of beta cell failure
US20080090759A1 (en) 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
FI20050011L (fi) 2005-01-05 2006-07-06 Jurilab Ltd Oy Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
ITVI20050059A1 (it) 2005-03-04 2006-09-05 Consorzio Per Gli Studi Universitari In Verona Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
EP2604703B1 (en) 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Methods for evaluating graft survival in a solid organ transplant recipient
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1871909A4 (en) 2005-03-31 2010-05-19 Univ Leland Stanford Junior COMPOSITIONS AND METHODS OF DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDER
CN101248180B (zh) 2005-04-18 2013-09-25 米托米克斯公司 作为检测日光照射、前列腺癌和其它癌症的诊断工具的线粒体突变及重排
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
EP1915614A4 (en) 2005-07-21 2009-03-25 Univ Johns Hopkins METHOD FOR DETECTING AND TREATING AN ACUTE KIDNEY INJURY
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
WO2007041623A2 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20080090304A1 (en) 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8329408B2 (en) 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US10716749B2 (en) 2005-11-03 2020-07-21 Palo Alto Investors Methods and compositions for treating a renal disease condition in a subject
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
TW200726845A (en) 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
BRPI0621006A2 (pt) 2006-01-20 2011-11-29 Mosaiques Diagnostics & Therap método e marcadores para o diagnóstico de doenças renais
WO2007106781A2 (en) 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
WO2007124331A2 (en) 2006-04-19 2007-11-01 Virginia Commonwealth University Cardioprotective and other uses of mammalian target of rapamycin (m-tor) inhibitors
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20080038269A1 (en) 2006-05-25 2008-02-14 Mount Sinai Hospital Methods for detecting and treating kidney disease
US7972795B2 (en) 2006-06-20 2011-07-05 Institut De Cardiologie De Montreal Angiopoietin-like 2 as a biomarker of vascular endothelial cell abnormal function and senescence
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
US20090298073A1 (en) 2006-06-30 2009-12-03 Gerhold David L Kidney Toxicity Biomarkers
US20090176656A1 (en) 2006-07-21 2009-07-09 Halloran Philip F Tissue rejection
GB0617429D0 (en) 2006-09-05 2006-10-18 Electrophoretics Ltd Markers of renal transplant rejection and renal damage
US20080206794A1 (en) 2006-09-15 2008-08-28 Renovar Incorporated Systems And Methods For Characterizing Contrast Induced-Nephropathy
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
WO2008060607A2 (en) 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
CA2665489C (en) 2006-12-08 2017-08-29 The Children's Hospital Of Philadelphia Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GB0701626D0 (en) 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
EP2479569A3 (en) 2007-03-26 2012-09-26 Novartis AG Predictive renal safety biomarkers and biomarker signatures to monitor kidney function
WO2008122670A2 (en) 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
TWI367949B (en) 2007-04-10 2012-07-11 Univ Nat Taiwan Predicting post-treatment survival in cancer patients with microrn
US8080394B2 (en) 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
WO2008150488A1 (en) 2007-06-01 2008-12-11 Laboratory Corporation Of America Holdings Methods and systems for quantification of peptides and other analytes
JP5661457B2 (ja) 2007-06-06 2015-01-28 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 腎疾患の予測診断
US20090047689A1 (en) 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
US20100267041A1 (en) 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US8039227B2 (en) 2007-09-20 2011-10-18 University Of Louisville Research Foundation, Inc. Peptide biomarkers predictive of renal function decline and kidney disease
US20110059537A1 (en) 2007-09-20 2011-03-10 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
US8003333B2 (en) 2007-09-28 2011-08-23 Mayo Foundation For Medical Education And Research Serum biomarkers for early detection of acute cellular rejection
CN101910845A (zh) 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
MX2010004671A (es) 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
US8592925B2 (en) 2008-01-11 2013-11-26 Seiko Epson Corporation Functional device with functional structure of a microelectromechanical system disposed in a cavity of a substrate, and manufacturing method thereof
KR20100122495A (ko) 2008-02-29 2010-11-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도
US20090298106A1 (en) 2008-05-30 2009-12-03 Therapeutic Monitoring Services, L.L.C. Methods for Monitoring Immunosuppressant Drug Levels, Renal Function, and Hepatic Function Using Small Volume Samples
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2149613A1 (en) 2008-07-28 2010-02-03 Greenwood Genetic Center, Inc. Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders
US8673574B2 (en) 2008-08-21 2014-03-18 Pxbiosciences Llc Diagnosis and monitoring of renal failure using peptide biomarkers
JP2012501456A (ja) 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
US20110256560A1 (en) 2008-10-20 2011-10-20 University Health Network Methods and compositions for the detection of ovarian cancer
ES2836218T3 (es) 2008-10-21 2021-06-24 Astute Medical Inc Procedimientos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
CA2740923A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2394166B1 (en) 2009-02-06 2016-07-13 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012522491A (ja) 2009-04-03 2012-09-27 ベジニクス ピーティーワイ リミテッド 抗ｖｅｇｆ−ｄ抗体
US8313949B2 (en) 2009-04-16 2012-11-20 Nextcea Inc. Detecting phospholipidosis and diagnosing lysosomal storage disorders
WO2010122231A1 (en) 2009-04-23 2010-10-28 Wallac Oy Methods for determining maternal health risks
WO2010128158A1 (en) 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders
US8974491B2 (en) 2009-06-23 2015-03-10 Infarct Reduction Technologies Inc. Methods for adaptive limb occlusion
NZ598035A (en) 2009-08-07 2014-06-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462437A4 (en) 2009-08-07 2013-01-30 Rules Based Medicine Inc METHOD AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISEASES THEREOF
US20120315649A1 (en) 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2774223A1 (en) 2009-09-21 2011-03-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120156701A1 (en) 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ701807A (en) 2010-02-26 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011109830A2 (en) 2010-03-05 2011-09-09 Case Western Reserve University Protein biomarkers and therapeutic targets for renal disorders
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130210043A1 (en) 2010-06-23 2013-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130035290A1 (en) 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
WO2013006629A1 (en) 2011-07-06 2013-01-10 Alere San Diego Inc. Methods and compositions for assigning likelihood of acute kidney injury progression
PT2748605T (pt) 2011-08-26 2019-05-03 Astute Medical Inc Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP2923204A1 (en) 2012-10-31 2015-09-30 Astute Medical, Inc. Quantitative lateral flow assay
CN108120837B (zh) 2012-11-09 2021-06-22 霍夫曼-拉罗奇有限公司 阵发性心房纤颤的基于TnT的诊断
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
TWI558403B (zh) 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
US20160146832A1 (en) 2013-06-05 2016-05-26 Lakhmir S. Chawla Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20160039682A (ko) 2013-08-07 2016-04-11 아스튜트 메디컬 인코포레이티드 생물학적 샘플에서 개선된 성능을 가지는 timp2에 대한 검정
JP2017501211A (ja) 2013-11-06 2017-01-12 アスチュート メディカル，インコーポレイテッド 生体試料中で改善された性能を有するｉｇｆｂｐ７のためのアッセイ
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN108139409B (zh) 2015-10-08 2020-07-24 豪夫迈·罗氏有限公司 当在外科手术之前测量时用于预测aki的风险的igfbp7
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
CN110352073A (zh) 2016-10-28 2019-10-18 机敏医药股份有限公司 针对timp-2的抗体用于改善肾功能的用途
CN110431422A (zh) 2017-02-06 2019-11-08 机敏医药股份有限公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN110709103B (zh) 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
CN110753700A (zh) 2017-05-07 2020-02-04 机敏医药股份有限公司 胰岛素样生长因子结合蛋白7和金属蛋白酶2组织抑制物在肾脏替代疗法的管理中的用途

Also Published As

Publication number Publication date
EP2513649A1 (en) 2012-10-24
US20170343562A1 (en) 2017-11-30
NZ702527A (en) 2016-07-29
EP3112871B1 (en) 2020-07-29
KR102003258B1 (ko) 2019-07-24
JP2015064371A (ja) 2015-04-09
US10830773B2 (en) 2020-11-10
JP2013515243A (ja) 2013-05-02
US12123882B2 (en) 2024-10-22
AU2014227447A1 (en) 2014-10-02
CA2784889A1 (en) 2011-06-23
HK1171260A1 (en) 2013-03-22
EP3112871A1 (en) 2017-01-04
WO2011075744A1 (en) 2011-06-23
EP2513649A4 (en) 2013-07-03
NZ600828A (en) 2014-09-26
KR20180063352A (ko) 2018-06-11
JP6309434B2 (ja) 2018-04-11
EP2513649B1 (en) 2016-04-20
US20220187319A1 (en) 2022-06-16
US11262363B2 (en) 2022-03-01
AU2010330735A1 (en) 2012-07-19
KR20120123056A (ko) 2012-11-07
NZ625423A (en) 2015-02-27
HK1211082A1 (en) 2016-05-13
ES2818138T3 (es) 2021-04-09
EA201290387A1 (ru) 2013-02-28
CN102725636A (zh) 2012-10-10
CA2784889C (en) 2018-06-19
MX2012007082A (es) 2012-11-06
AU2010330735B2 (en) 2014-11-27
ES2592386T3 (es) 2016-11-29
US20120283128A1 (en) 2012-11-08
CN104698161A (zh) 2015-06-10
JP5763098B2 (ja) 2015-08-12
CN102725636B (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
MX342967B (es) Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
MX346096B (es) Métodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
NZ592488A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2012005210A (es) Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
MX2011002233A (es) Metodos y composiciones para la diagnosis y prognosis de daño renal y falla renal.
Samnegård et al. Serum matrix metalloproteinase‐3 concentration is influenced by MMP‐3− 1612 5A/6A promoter genotype and associated with myocardial infarction
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013515243A5 (https=)
MX2011004174A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal e insuficiencia renal.
FR2919063B1 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
WO2007070359A3 (en) Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
MX2012005218A (es) Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
WO2011097541A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Wang et al. Risk factors for mortality in patients with septic acute kidney injury in intensive care units in Beijing, China: a multicenter prospective observational study
IL247111B2 (en) Preventive or therapeutic agent for kidney disease
Pawlak et al. Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients
Helmersson-Karlqvist et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men
Quan et al. Review of early circulating biomolecules associated with diabetes nephropathy–Ideal candidates for early biomarker array test for DN
EA201290106A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
Reichel Acute kidney injury: quoi de neuf?
IN2012MN02812A (https=)
WO2012008991A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FG Grant or registration